Efficacy Evaluation of Lubiprostone on Non-Alcoholic Fatty Liver Disease (NAFLD)wih constipation: LUBIPRONE, Proof of Concept(POC) Study. - LUBIPRONE, Proof of Concept(POC) Study.

Yokohama University School of Medicine0 个研究点目标入组 150 人开始时间: 2017年3月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with any change to their oral medications within 3 months before informed consent 2)Patients with any contraindications listed on the package insert for lubiprostone or with a history of hypersensitivity to any ingredients of lubiprostone 3)Patients with any other concurrent liver disease, such as hepatitis C, hepatitis B, or autoimmune hepatitis 4)Patients with concurrent or past history of any serious cardiac, vascular, hematological, respiratory, hepatic, renal, gastrointestinal, or neuropsychiatry disease 5)Patients with drug-induced, symptomatic NAFLD 6)Patients who participated in any other clinical study and received study treatment within 1 month before the start of this research (counted from the first day of study medication) 7)Patients with diabetes mellitus being treated with insulin injections 8)Patients with a history of abdominal or gastrointestinal surgery, with the exception of appendicitis 9)Breastfeeding women, or women with possible pregnancy 10)Other patients who are inappropriate as participants in this research in the opinion of the principal investigator etc.

发起方

Yokohama University School of Medicine